Skip to main content

Table 2 Proteolytic enzymes, CEA and CA 19-9 in correlation with Dukes classification.

From: Tumor marker utility and prognostic relevance of cathepsin B, cathepsin L, urokinase-type plasminogen activator, plasminogen activator inhibitor type-1, CEA and CA 19-9 in colorectal cancer

Stage CATB CATL uPA PAI-1 CEA CA 19-9
DUKES A (n = 7) 4.50
(2.4–37.3)
1.10
(1.0–35.3)
0.30
(0.2–0.62)
32.81
(17.2–66.7)
3.00
(0.6–3.4)
6.80
(3.0–11.5)
DUKES B (n = 12) 6.75
(3.2–23.8)
1.00
(1.0–12.3)
0.29
(0.1–0.79)
39.09
(13.5–108.1)
2.00
(0.6–21.1)
7.65
(1.0–35.0)
DUKES C (n = 23) 8.60
(3.6–35.7)
1.10
(1.0–34.1)
0.26
(0.1–0.79)
52.54
(13.8–126.4)
2.20
(0.4–235.0)
9.20
(1.0–78.6)
DUKES D (n = 14) 24.25*§
(9.2–39.3)
4.55
(1.0–35.2)
0.29
(0.12–0.42)
82.03**
(38.7–138.6)
8.30#
(1.9–74.6)
35.85**
(4.6–540.0)
Kruskall-Wallis analysis of variance (P value) P = 0.0002 P = NS P = NS P = 0.01 P = 0.003 P = 0.001
  1. Cathepsin B, cathepsin L, urokinase-type plasminogen activator, plasminogen activator inhibitor type-1, CEA and CA 19-9 levels in association with Dukes classification of colorectal cancer expressed in ng/ml (median values and range)
  2. Statistics:
  3. *P < 0.01, Dukes D vs Dukes A and B
  4. §P < 0.05, Dukes D vs Dukes C
  5. **P < 0.05, Dukes D vs Dukes A, B and C
  6. #P < 0.01, Dukes D vs Dukes A, B and C
  7. Abbreviations: DUKES A: Dukes stage A; DUKES B: Dukes stage B; DUKES C: Dukes stage C; DUKES D: Dukes stage D; CATB: cathepsin B; CATL: cathepsin L; uPA: urokinase-type plasminogen activator, PAI-1: plasminogen activator inhibitor type-1; CEA: carcinoembryonic antigen; CA 19-9: carbohydrate antigen 19-9; NS: not significant